Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Top 10 Pharmaceutical Companies in India: Growth strategies, performance and SWOT analyses
Report
Published: July 2009
Pages: 169
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 2396.88 Buy Now!
Research from: Business Insights
Sector: Corporate & Fiscal
The leading players in the Indian pharmaceutical market comprise both India-based and MNCs. This report provides an insight to the current state of Indian pharmaceutical industry as well as the evolving trends. This report analyzes the Indian pharmaceutical industry in light of market size, key drivers and resistors, trends and competitive positioning in the global market. It also analyzes the competitive landscape of the industry based on financial and operational (field force strength, R&D spend, exposure to chronic therapeutic areas and the US pharmaceutical market) parameters.
This report also compares and analyzes the competitive positioning of Indian pharmaceutical market in the context of global pharmaceutical market. The report also includes profiles of the top ten companies in the industry and also involves a brief summary of top 11 to 20 players.
The top 10 companies in the Indian pharmaceutical industry were assessed on following parameters:
• market share in the Indian pharmaceutical market;
• marketed products and therapeutic focus;
• growth strategies and major acquisitions and divestments in this market;
• key partnerships and alliances formed by these companies;
• business-related strengths and weaknesses of these companies, and insights into the opportunities and threats facing them.
Key findings
The Indian pharmaceutical market was valued at $7,743m in 2008, an increase of 4.0% over 2007. Business Insights anticipates that Indian pharmaceutical market will grow at a faster pace than the global pharmaceutical market, approximately at a CAGR of 13.2% during 2009–14 to reach a total value of $15,490m in 2014.
India has emerged as a key destination for global pharmaceutical companies due to its high growth prospects led by ageing population, changing disease profile, and improving patent regime and socio-economic conditions.
The Indian pharmaceutical market is highly competitive and fragmented with the top 10 players accounting for 36.1% of the total R&H sales in 2008.
India started to comply with World Trade Organization’s Trade Related Aspects of Intellectual Property Rights (WTO-TRIPS) agreement and recognized product patents with the amendment of the Indian Patent Act in January 2005. Indian companies plan to capitalize on Japanese government initiatives to promote generic drugs to reduce healthcare costs.
Use this report to
• Learn from the strategies of the Indian pharmaceutical companies to target future growth markets effectively, avoid their mistakes, replicate their successes and learn of the threats they face.
• Benchmark your performance against the leading Indian pharmaceutical companies using market share data by company and comprehending their strategies.
• Understand the major issues affecting the Indian pharmaceutical market.
• Predict the key growth areas in the Indian pharmaceuticals market arising from the change in the lifestyle of consumers and strengthening of the IPR regime in India.
• Save time, money and resources on analyzing the performance of the key Indian pharmaceutical companies using this report.
Key issues
Inadequacies in the new patent regime: Provisions related to Sec 3(d) of the Patent (Amendment) Act 2005 prevent ever-greening of drug patents as it does not allow patenting new uses of an existing drug. In addition, compulsory licensing allows Indian players to continue manufacturing generics of patented products for export to underdeveloped countries.
Lack of infrastructure: Problems related to frequent power cuts and lack of proper transport infrastructure will slowdown the growth of the industry.
Limited funds: Limited funding from FIs, venture capitalists and the government may slowdown the development of biotechnology industry in India.
Regulatory hurdles: Increasing due diligence and compliance with standards leads to cost overrunning and delay in new product launches.
Intense competition: Strong pricing competition among local manufacturers leads to low margins and limited capital to support R&D. Competition will further intensify from big generic players participating in the Indian market to leverage the cost advantage and large resource pool.
Discover
• What was the market size of the Indian pharmaceutical market in 2008?
• What will be the market size of the Indian pharmaceutical market during 2009-14?
• What are the trends in the Indian pharmaceutical market?
• Who are the top 20 players in the market?
• What is the market share of each of the top 10 companies?
• What are the growth strategies of the top 10 companies?
• What are the strengths of the top 10 players in the Indian pharmaceutical market?
• What are the growth opportunities for the global top 10 Indian pharmaceutical companies?
• What is the most contentious issue facing the Indian pharmaceutical market?
This report also compares and analyzes the competitive positioning of Indian pharmaceutical market in the context of global pharmaceutical market. The report also includes profiles of the top ten companies in the industry and also involves a brief summary of top 11 to 20 players.
The top 10 companies in the Indian pharmaceutical industry were assessed on following parameters:
• market share in the Indian pharmaceutical market;
• marketed products and therapeutic focus;
• growth strategies and major acquisitions and divestments in this market;
• key partnerships and alliances formed by these companies;
• business-related strengths and weaknesses of these companies, and insights into the opportunities and threats facing them.
Key findings
The Indian pharmaceutical market was valued at $7,743m in 2008, an increase of 4.0% over 2007. Business Insights anticipates that Indian pharmaceutical market will grow at a faster pace than the global pharmaceutical market, approximately at a CAGR of 13.2% during 2009–14 to reach a total value of $15,490m in 2014.
India has emerged as a key destination for global pharmaceutical companies due to its high growth prospects led by ageing population, changing disease profile, and improving patent regime and socio-economic conditions.
The Indian pharmaceutical market is highly competitive and fragmented with the top 10 players accounting for 36.1% of the total R&H sales in 2008.
India started to comply with World Trade Organization’s Trade Related Aspects of Intellectual Property Rights (WTO-TRIPS) agreement and recognized product patents with the amendment of the Indian Patent Act in January 2005. Indian companies plan to capitalize on Japanese government initiatives to promote generic drugs to reduce healthcare costs.
Use this report to
• Learn from the strategies of the Indian pharmaceutical companies to target future growth markets effectively, avoid their mistakes, replicate their successes and learn of the threats they face.
• Benchmark your performance against the leading Indian pharmaceutical companies using market share data by company and comprehending their strategies.
• Understand the major issues affecting the Indian pharmaceutical market.
• Predict the key growth areas in the Indian pharmaceuticals market arising from the change in the lifestyle of consumers and strengthening of the IPR regime in India.
• Save time, money and resources on analyzing the performance of the key Indian pharmaceutical companies using this report.
Key issues
Inadequacies in the new patent regime: Provisions related to Sec 3(d) of the Patent (Amendment) Act 2005 prevent ever-greening of drug patents as it does not allow patenting new uses of an existing drug. In addition, compulsory licensing allows Indian players to continue manufacturing generics of patented products for export to underdeveloped countries.
Lack of infrastructure: Problems related to frequent power cuts and lack of proper transport infrastructure will slowdown the growth of the industry.
Limited funds: Limited funding from FIs, venture capitalists and the government may slowdown the development of biotechnology industry in India.
Regulatory hurdles: Increasing due diligence and compliance with standards leads to cost overrunning and delay in new product launches.
Intense competition: Strong pricing competition among local manufacturers leads to low margins and limited capital to support R&D. Competition will further intensify from big generic players participating in the Indian market to leverage the cost advantage and large resource pool.
Discover
• What was the market size of the Indian pharmaceutical market in 2008?
• What will be the market size of the Indian pharmaceutical market during 2009-14?
• What are the trends in the Indian pharmaceutical market?
• Who are the top 20 players in the market?
• What is the market share of each of the top 10 companies?
• What are the growth strategies of the top 10 companies?
• What are the strengths of the top 10 players in the Indian pharmaceutical market?
• What are the growth opportunities for the global top 10 Indian pharmaceutical companies?
• What is the most contentious issue facing the Indian pharmaceutical market?